Replies to post #175767 on Biotech Values

[DewDiligence]

My assumption on ABBV pricing much lower is 50-50 - they say they won't but I can't believe they can't see through this - so I can't make assumptions on pricing. From investment point of view in case like this, I prepare for both outcomes.

Well, whatever you end up doing, you’re making an implicit probability-based assumption about HCV pricing and market dynamics.

I think it’s pretty clear that, rhetoric aside, ABBV will price at a 20-30% aggregate discount to Sovaldi + Ledipasvir. (I use the word aggregate because the discount for any given subgroup may vary depending on treatment duration.)